A Disintegrin And Metalloproteinase
From Proteopedia
(Difference between revisions)
| Line 9: | Line 9: | ||
* '''ADAM33''' is implicated in asthma.<br /> | * '''ADAM33''' is implicated in asthma.<br /> | ||
* '''ADAMTS''' is ADAM with thrombospondin motifs<ref>PMID:15554875</ref>. <br /> | * '''ADAMTS''' is ADAM with thrombospondin motifs<ref>PMID:15554875</ref>. <br /> | ||
| - | * '''ADAMTS1''' has anti-angionenic activity. <br /> | + | * '''ADAMTS1''' has anti-angionenic activity<ref>PMID:10811842</ref>. <br /> |
* '''ADAMTS4''' and '''ADAMTS5''' are involved in the degradation of aggrecan.<br /> | * '''ADAMTS4''' and '''ADAMTS5''' are involved in the degradation of aggrecan.<br /> | ||
| - | * '''ADAMTS13''' cleaves [[Von Willebrand Factor]] involved in blood clotting | + | * '''ADAMTS13''' cleaves [[Von Willebrand Factor]] involved in blood clotting<ref>PMID:18762209</ref>. |
| - | <ref>PMID:18762209</ref> | + | |
== Disease == | == Disease == | ||
| - | ADAM inhibitors are used in anti-cancer therapy. ADAM10 is a therapeutic target for cancer and inflammation <ref>PMID:19601831</ref>. ADAM17 is a therapeutic target for multiple diseases <ref>PMID:19601834</ref>.ADAM33 is implicated in asthma. | + | ADAM inhibitors are used in anti-cancer therapy. '''ADAM10''' is a therapeutic target for cancer and inflammation <ref>PMID:19601831</ref>. '''ADAM17''' is a therapeutic target for multiple diseases <ref>PMID:19601834</ref>. '''ADAM33''' is implicated in asthma. '''ADAM33''' is a therapeutic target for asthma <ref>PMID:38396994</ref>. '''ADAMTS4''' is involved in various CNS pathologies<ref>PMID:28084617</ref>. |
== 3D Structures of A Disintegrin And Metalloproteinase == | == 3D Structures of A Disintegrin And Metalloproteinase == | ||
Current revision
| |||||||||||
References
- ↑ Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J. 2005 Feb 15;386(Pt 1):15-27. PMID:15554875 doi:10.1042/BJ20040424
- ↑ Shindo T, Kurihara H, Kuno K, Yokoyama H, Wada T, Kurihara Y, Imai T, Wang Y, Ogata M, Nishimatsu H, Moriyama N, Oh-hashi Y, Morita H, Ishikawa T, Nagai R, Yazaki Y, Matsushima K. ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. J Clin Invest. 2000 May;105(10):1345-52. PMID:10811842 doi:10.1172/JCI8635
- ↑ Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008 Oct;29(5):258-89. doi: 10.1016/j.mam.2008.08.001. Epub 2008, Aug 15. PMID:18762209 doi:http://dx.doi.org/10.1016/j.mam.2008.08.001
- ↑ Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des. 2009;15(20):2288-99. PMID:19601831 doi:10.2174/138161209788682442
- ↑ Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009;15(20):2319-35. PMID:19601834 doi:10.2174/138161209788682398
- ↑ Sleziak J, Gawor A, Błażejewska M, Antosz K, Gomułka K. ADAM33's Role in Asthma Pathogenesis: An Overview. Int J Mol Sci. 2024 Feb 15;25(4):2318. PMID:38396994 doi:10.3390/ijms25042318
- ↑ Lemarchant S, Wojciechowski S, Vivien D, Koistinaho J. ADAMTS-4 in central nervous system pathologies. J Neurosci Res. 2017 Sep;95(9):1703-1711. PMID:28084617 doi:10.1002/jnr.24021
